Drug Trial Radar · NCT06681324
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Dec 11, 2024
Primary completion
Aug 10, 2026
Study completion Sep 3, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn's disease and an ileostomy.
Conditions
- Crohn's Disease
Interventions
AZD7798Drug
AZD7798
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: from Week 0 to Week 12
- Number of participants with abnormal Vital signs: Blood pressureTime frame: from Week 0 to Week 12
- Number of participants with abnormal Vital signs: Pulse rateTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in haematology: complete blood count (CBC)Time frame: from Week 0 to Week 12
- Number of participants with abnormal values in haematology: white blood cell (WBC) countTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in haematology: RBCTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in clinical chemistry: kidney functionTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in clinical chemistry: electrolytesTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in clinical chemistry: liver functionTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in clinical chemistry: hs-CRPTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in clinical chemistry: glucoseTime frame: from Week 0 to Week 12
- Number of participants with abnormal values in ECG readingsTime frame: from Week 0 to Week 12
Locations
17 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Leuven, Belgium
Research Site
Padova, Italy
Research Site
Roma, Italy
Research Site
Rozzano, Italy
Research Site
Amsterdam, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Warsaw, Poland
Research Site
Linköping, Sweden
Research Site
Stockholm, Sweden
Research Site
Kyiv, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Vinnytsia, Ukraine
Research Site
Birmingham, United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.